Population and treatment-based incidence estimates of atypical fractures

Christian M Girgis and Markus J Seibel
Med J Aust 2011; 194 (12): . || doi: 10.5694/j.1326-5377.2011.tb03163.x
Published online: 20 June 2011

To the Editor: Atypical femur fractures appear to be an emerging adverse outcome of long-term use of bisphosphonates. Although analyses of epidemiological data suggest that subtrochanteric and diaphyseal fractures per se are rare,1,2 the true incidence of atypical fractures (a distinct subset of such fractures) is unknown.

  • Christian M Girgis
  • Markus J Seibel

  • University of Sydney, Sydney, NSW.


Competing interests:

Markus Seibel is a member of advisory boards for Merck Sharp and Dohme, Novartis, Amgen and Sanofi-Aventis. He has also received funding from these companies for institutional research.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.